Phase 2Recruiting
Fisetin to Reduce Senescence and Mobility Impairment in PAD (FIRST)
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
- Sponsor
- Northwestern University (Academic or other)
- Enrolment
- 34 planned
- Conditions
- Peripheral Arterial Disease; Aging; Peripheral Vascular Diseases; Walking, Difficulty; Claudication
- Interventions
- Fisetin; Placebo
- Ages
- adults, older adults
- Registry
- NCT06399809
From the registry
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.
Primary outcomes
- Six-minute Walk Distance